BCR and B-cell chronic lymphocytic leukemia: Although immunochemotherapy tailored to patients’ fitness has so far remained the backbone of frontline CLL treatment in the majority of patients, the development of novel selective compounds targeting the B cell receptor (BCR), along with increasing knowledge of predictive factors, have improved patients’ prognosis [3,4].